THE SCIENCE OF METABOLIC HEALTH
Metabolic health,
made youthful.
Obesity, insulin resistance and metabolic disease are treatable biology, not personal failings. Clear, current evidence on GLP-1 medicines, muscle, nutrition and sleep, curated by a physician board-certified in obesity medicine.
GLP-1 & GIP
Insulin resistance
Body composition
Liver fat (MASLD)
Muscle & strength
Sleep & appetite
Cardiometabolic risk
Clinical obesity
Nutrition therapy
Metabolic surgery
START WHERE YOU ARE
Six ways into the library
Every guide is written and reviewed by Farhan Tahir, MD, and cites the evidence behind it.
01
Conditions
Obesity, prediabetes, diabetes, fatty liver and metabolic heart risk.
Explore →
02
Medications
GLP-1 medicines, other weight-loss drugs, metformin, SGLT2 inhibitors and surgery.
Explore →
03
Tests & imaging
A1c, ApoB, Lp(a), FIB-4 and body composition, decoded.
Explore →
04
Living well
Protein, strength, nutrition, sleep and keeping weight off.
Explore →
05
Video library
Physician-taught lessons with animated explainers.
Explore →
06
For clinicians
Guideline-based prescribing and risk summaries.
Explore →
Metabolic health
Metabolism, made visible.
Nutrition, muscle, glucose and body composition. The everyday building blocks of metabolic health.
Protein-forward meals
Resistance training
Glucose monitoring
DEXA body scan
Walking after meals
Meal planning
Lab review
Muscle as medicine
Hydration
Sleep & appetite
Physician check-in
Healthy weight journey
OUR THESIS
Weight is a number. Metabolic health is a system.
For decades, care started and ended with BMI. In January 2025 a 58-member Lancet Diabetes & Endocrinology Commission asked a better question: is excess body fat already changing how your organs and body work? That shift, from weight to function, is how we think about metabolism here.
Youthful Metabolism translates the fast-moving science of incretin medicines, body composition and metabolic disease into plain language. Every claim links to a primary source and carries an honest evidence label.
PRECLINICAL OBESITY
Excess fat, organs still working
Body fat is above a healthy range but tissues and daily function are preserved. Risk is rising. The plan: monitoring, counseling and risk reduction.
CLINICAL OBESITY
Excess fat already causing illness
Excess adiposity is already impairing organ function or limiting daily life. A chronic disease that warrants timely, evidence-based treatment.
Source: Rubino et al., Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262.
THE METABOLIC GAP, IN NUMBERS
Most adults are metabolically unwell. Most of it is treatable.
40.3%
of US adults have obesity
CDC NHANES, Aug 2021–Aug 2023
6.8%
of US adults had optimal cardiometabolic health in 2017–2018
O’Hearn et al., JACC 2022
20%
fewer major cardiovascular events with semaglutide vs placebo in SELECT
Lincoff et al., NEJM 2023
28.3%
mean weight loss with retatrutide 12 mg at 80 weeks, still investigational
TRIUMPH-1 topline, Eli Lilly, May 2026
THE YOUTHFUL METABOLISM STANDARD
Four pillars. One metabolism.
Obesity medicine rests on four pillars. Medicines are powerful, but they work best, and their results last longest, when the other three are in place.
01
Nutrition therapy
Protein-forward, fiber-rich, minimally processed eating that protects muscle and steadies glucose. No single diet wins; adherence does.
02
Physical activity
Muscle-strengthening work at least twice a week plus 150–300 minutes of moderate activity, per the US Physical Activity Guidelines.
03
Sleep, stress & behavior
Sleep and stress reshape appetite hormones. Small, repeatable routines outperform willpower over months and years.
04
Medical treatment
GLP-1-based medicines, other prescriptions and metabolic surgery when the biology calls for them, always physician-supervised.
CONDITION GUIDES
Start with the condition
Weight & obesity
Obesity
A chronic disease of excess body fat. The 2025 Lancet Commission separates obesity that is already harming the body from obesity that raises future risk.
Read the guide →
Blood sugar & liver
Prediabetes & insulin resistance
Blood sugar above normal but below diabetes. The best window to prevent type 2 diabetes.
Read the guide →
Blood sugar & liver
Type 2 diabetes
Chronically high blood sugar from insulin resistance and failing insulin secretion. Modern medicines protect heart, kidneys and weight.
Read the guide →
Blood sugar & liver
Fatty liver disease (MASLD and MASH)
Fat in the liver driven by metabolic risk. Common, silent and now treatable when inflammation and scarring develop.
Read the guide →
HOW THE NEW MEDICINES WORK
Four hormone signals. One conversation between gut and brain.
Today’s most effective obesity medicines mimic hormones your gut already makes after a meal. Tap each signal to see where it acts.
Glucagon-like peptide-1
Semaglutide, liraglutide and orforglipron. Also one of the signals in tirzepatide and retatrutide.
Simplified schematic for education. “Proposed” marks effects supported mainly by animal or mechanistic studies.
THE EVIDENCE
What the pivotal trials actually showed.
Average results from the trials that put these medicines on the map, next to placebo. Individual responses vary widely, and trials are not head-to-head comparisons.
Each trial enrolled different people for different lengths of time and used different statistical approaches, so this is not a head-to-head comparison. Sources: Wilding et al., NEJM 2021 (STEP 1); Jastreboff et al., NEJM 2022 (SURMOUNT-1); Wharton et al., NEJM 2025 (OASIS 4); ATTAIN-1 as reported at FDA approval, April 2026; Eli Lilly topline release, May 21, 2026 (TRIUMPH-1).
PROTECT WHAT MATTERS
Lose fat. Keep the muscle.
On GLP-1-based medicines, lean tissue can account for roughly a quarter to two-fifths of the weight lost, depending on the study and how it is measured. Muscle drives strength, glucose control and healthy aging, so we pair every medicine with resistance training, adequate protein and body-composition tracking.
Sources: Neeland et al., Diabetes Obes Metab 2024; Conte et al., JAMA 2024.
TREATMENTS, WITH HONEST LABELS
Every option, rated by the evidence.
From weekly injections to the newest pills and the investigational triple agonist, each treatment page explains how it works, what trials showed and what to watch for.
FDA-approved
Semaglutide
The GLP-1 medicine that showed obesity treatment can protect the heart.
≈15% mean weight loss at 68 weeks
Read the evidence →
FDA-approved
Tirzepatide
Two incretin signals in one weekly injection.
≈21% mean weight loss at 72 weeks (15 mg)
Read the evidence →
FDA-approved
Orforglipron
A once-daily GLP-1 pill with no food or water rules.
≈11% mean weight loss at 72 weeks (36 mg)
Read the evidence →
Investigational
Retatrutide
The triple agonist pushing medical weight loss toward surgical results.
28.3% mean weight loss at 80 weeks (topline)
Read the evidence →
THE RESEARCH DESK
What changed in metabolic science this month.
Every update summarizes a primary source, labels the strength of evidence and says plainly what it does not prove.
Clinical Trials
Retatrutide reports 28.3% mean weight loss in phase 3 TRIUMPH-1
Eli Lilly’s topline results show all three doses of the GIP/GLP-1/glucagon triple agonist met their endpoints at 80 weeks in adults with obesity or overweight without diabetes. The 12 mg dose produced a mean 28.3% weight loss, and 45.3% of participants lost at least 30% of body weight.
Human RCT · topline
Regulatory
FDA approves orforglipron (Foundayo), a GLP-1 pill without food or water rules
The FDA approved Eli Lilly’s orforglipron for adults with obesity, or overweight with a weight-related condition, after a 50-day review under a new priority program. In ATTAIN-1, the 36 mg dose produced a mean 11.2% weight loss at 72 weeks versus 2.1% on placebo.
Regulatory decision
Regulatory
Wegovy becomes the first GLP-1 pill approved for weight management
The FDA approved oral semaglutide 25 mg once daily to reduce excess body weight, maintain weight reduction and lower the risk of major cardiovascular events. In OASIS 4, participants lost a mean 16.6% of body weight at 64 weeks on treatment versus 2.7% on placebo.
Regulatory decision
WHO THIS IS FOR
One evidence base, three ways in.
FOR THE CURIOUS
Understand your metabolism
Plain-language explainers on appetite, insulin, fat tissue and muscle, without diet-culture noise.
Start with the science →
FOR PATIENTS ON GLP-1 THERAPY
Get more from your treatment
What to expect, how to protect muscle, what to do about side effects and what new trials mean for you.
Compare treatments →
FOR CLINICIANS
Primary sources, labeled
Evidence labels, trial context and biweekly research updates built for fast, critical reading.
Read the research →
WHY WE BUILT THIS
“Obesity is biology, not a character flaw. Our job is to turn fast-moving science into care that protects muscle, metabolism and dignity.”
Farhan Tahir, MD · Founder, Youthful Vitality & Longevity Medicine
Farhan Tahir, MD, FACR, Dip. ABOM
FOUNDER & MEDICAL EDITOR
Quadruple board-certified in internal medicine, rheumatology, integrative medicine and obesity medicine, with more than 20 years of practice across academic, hospital, infusion and telemedicine settings. He leads Youthful Vitality & Longevity Medicine in Doylestown, PA and Manhattan.
FROM THE STUDIO
Video lessons
Short lessons with Dr. Tahir, each paired with an animated explainer.
8 min
Obesity Is a Disease
Why obesity is a chronic disease of weight regulation, and what the 2025 Lancet Commission changed.
Watch the lesson →
7 min
How GLP-1 Medicines Work
From gut hormone to medicine: how semaglutide, tirzepatide and newer agents reduce appetite and improve metabolism.
Watch the lesson →
9 min
Tirzepatide vs Semaglutide
What head-to-head data show, how the two differ, and how to choose with your clinician.
Watch the lesson →
THE YOUTHFUL METABOLISM BRIEF
The science of metabolism, in your inbox every two weeks.
New research decoded in five minutes, with evidence labels and zero hype. We never sell or share your information.
Educational content only. Unsubscribe anytime.